Take a look back to prepare for the next generation of biotechnology patent litigation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Auth, D.R. Nat. Biotechnol. 15, 911 (1997).
149 F.3d 1368 (Fed. Cir. 1998), cert. denied, 525 U.S. 1093 (1999).
991 F.2d 781, 784 (Fed. Cir. 1993); see also In re Deuel, 51 F.3d 1552 (Fed. Cir. 1995).
31 U.S.P.Q. 2d 1027 (Bd Pt. App. & Int. 1993).
927 F.2d 1200, 1206 (Fed. Cir.), cert. denied sub. nom, Genetics Inst. v. Amgen, 502 U.S. 856 (1991).
188 F.3d 1362, 1375 (Fed. Cir. 1999).
In re Vaeck, 947 F.2d 488, 496 (Fed. Cir. 1991).
119 F.3d 1559 (Fed. Cir. 1997).
Kowalski, T.J. Nat. Biotechnol. 18, 349–350 (2000).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Locke, S., Kalow, D. When the Human Genome Project and State Street collide. Nat Biotechnol 18, 1009–1010 (2000). https://doi.org/10.1038/79281
Issue Date:
DOI: https://doi.org/10.1038/79281